Oncimmune Ltd. is seeking new distribution partners in the US as it expands the commercialization of its blood-based immunoassay for early-stage lung cancer, the only one of its kind in the market.
The EarlyCDT-Lung test works by measuring autoantibodies that are produced by the body in response to proteins produced by lung cancer cells. Research from Nottingham University in the UK, from which Oncimmune Ltd
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?